[The clinico-immunological efficacy of the likopid treatment of chronic bronchitis patients].

Abstract

AIM:

Elucidation of likopid effect on clinical and immunological pictures in patients with chronic bronchitis (CB).

MATERIALS AND METHODS:

A trial of 52 CB patients in remission and exacerbation. 2 schemes of likopid treatment were used: 1 mg/day for 10 days (a course dose 10 mg); 10 mg/day for 6 days (a course dose 60 mg). Clinical and laboratory parameters, systemic immunity (measurement of lymphocyte subpopulations, levels of serum IgA, IgM and IgG, functional activity of peripheral blood phagocytes).

RESULTS:

The 10 mg and 60 mg courses of likopid produced prolongation of remission to 5-6 months in 66% of CB patients in exacerbation and in 80% of patients in remission, respectively. 10 mg of likopid in exacerbation and 60 mg in remission promoted normalization of functional activity of blood phagocytes.

CONCLUSION:

Likopid administration for CB in a 10 mg course dose in exacerbation and 60 mg course in remission prolongs CB remission to 5-6 months and promoted normalization of phagocytic functional activity.

• Authors: A M Borisova, N Kh Setdikova, B V Pinegin, A V Kulakov, N M Golubeva
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 70 Issue 3 Pg. 38-40 ( 1998) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Kliniko-immunologicheskaia éffektivnost' lecheniia likopidom bol'nykh khronicheskim bronkhitom.
• PMID: 9575587 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Immunoglobulins
• glikopin
• Acetylmuramyl-Alanyl-Isoglutamine

Topics

• Acetylmuramyl-Alanyl-Isoglutamine (analogs & derivatives)
• Adjuvants, Immunologic (therapeutic use)
• Adolescent
• Adult
• Aged
• Bronchitis (drug therapy, immunology)
• Chronic Disease
• Humans
• Immunoglobulins (blood, drug effects)
• Lymphocyte Subsets (drug effects, immunology)
• Middle Aged
• Phagocytes (drug effects, immunology)
• Time Factors